Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Sep;118(9):1827-33.
doi: 10.1016/j.ophtha.2010.12.034. Epub 2011 Apr 20.

Economic considerations of macular edema therapies

William E Smiddy  1
Affiliations

Economic considerations of macular edema therapies

William E Smiddy. Ophthalmology. 2011 Sep.

Abstract

Purpose: To relate costs and treatment benefits for diabetic macular edema (DME), branch retinal vein occlusion (BRVO), and central retinal vein occlusion (CRVO).

Design: A model of resource use, outcomes, and cost-effectiveness and utility.

Participants: None.

Methods: Results from published clinical trials (index studies) of laser, intravitreal corticosteroids, intravitreal anti-vascular endothelial growth factor (VEGF) agents, and vitrectomy trials were used to ascertain visual benefit and clinical protocols. Calculations followed from the costs of 1 year of treatment for each treatment modality and the visual benefits as ascertained.

Main outcome measures: Visual acuity (VA) saved, cost of therapy, cost per line saved, cost per line-year saved, and costs per quality-adjusted life years (QALYs).

Results: The lines saved for DME (0.26-2.02), BRVO (0.74-4.92), and CRVO (1.2-3.75) yielded calculations of costs/line of saved VA for DME ($1329-$11,609), BRVO ($494-$13,039), and CRVO ($704-$7611); costs/line-year for DME ($60-$561), BRVO ($25-$754), and CRVO ($45-$473); and costs/QALY ($824 to $25,566).

Conclusions: Relative costs and benefits should be considered in perspective when applying and developing treatment strategies.

PubMed Disclaimer

Conflict of interest statement

The author does not have any financial interests to disclose.

Figures

Figure 1
Figure 1
Graph showing mean proportional costs of professional fees (pro), technical (tech), and, drug costs for the options of diabetic macular edema, branch retinal vein occlusion, central retinal vein occlusion. The two sets of columns of data for bevacizumab results are from the Pan American Collaborative Retina Study (PACORES) and Bevacizumab or Laser Therapy in the Management of Diabetic Macular Edema Study, Report #2 (BOLT-2), and the ranibizumab data are from the Diabetic Retinopathy Clinical Research (DRCR) study and Ranibizumab of Edema of the Macular in Diabetes Study, Report #2 (READ-2). Vitrectomy data is for treatment of diabetic macular edema only. (IVTA= intravitreal triamcinolone acetonide)
See this image and copyright information in PMC

References

    1. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 1985;103:1796–806. - PubMed
    1. Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch retinal vein occlusion. Am J Ophthalmol. 1984;98:271–82. - PubMed
    1. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion: the Central Vein Occlusion Study Group M report. Ophthalmology. 1995;102:1425–33. - PubMed
    1. Lin JM, Chiu YT, Hung PR, Tsai YY. Early treatment of severe cystoid macular edema in central retinal vein occlusion with posterior sub-Tenon triamcinolone acetonide. Retina. 2007;27:180–9. - PubMed
    1. Nakano S, Yamamoto T, Kirii E, et al. Steroid eye drop treatment (difluprednate ophthalmic emulsion) is effective in reducing refractory diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2010;248:805–10. - PubMed

Publication types

MeSH terms